scispace - formally typeset
T

Teresa S. Hawley

Researcher at National Institutes of Health

Publications -  27
Citations -  1696

Teresa S. Hawley is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Bone marrow & Viral vector. The author has an hindex of 16, co-authored 27 publications receiving 1654 citations. Previous affiliations of Teresa S. Hawley include University Medical Center & University of Würzburg.

Papers
More filters
Journal Article

Versatile retroviral vectors for potential use in gene therapy.

Robert G. Hawley, +3 more
- 01 Mar 1994 - 
TL;DR: A set of retroviral vectors whose capacity for high efficiency transduction of functional genes into undifferentiated murine embryonic and haematopoietic cells makes them ideally suited for preclinical studies with murine models and might prove useful in human gene therapy protocols.
Journal ArticleDOI

Transplantable myeloproliferative disease induced in mice by an interleukin 6 retrovirus.

Robert G. Hawley, +3 more
- 01 Oct 1992 - 
TL;DR: The results support an in vivo role of IL-6 in the maintenance of hematopoietic precursors in lethally irradiated mice transplanted with bone marrow cells infected with a novel recombinant retrovirus bearing a mouse IL- 6 gene.
Journal ArticleDOI

The myeloma-associated oncogene fibroblast growth factor receptor 3 is transforming in hematopoietic cells

Zhihua Li, +17 more
- 15 Apr 2001 - 
TL;DR: It is confirmed that FGFR3 is transforming and can produce lymphoid malignancies in mice and delayed pro-B-cell lymphoma/leukemias approximately 1 year after transplantation.
Journal Article

The HOX11 homeobox-containing gene of human leukemia immortalizes murine hematopoietic precursors.

Robert G. Hawley, +3 more
- 01 Jan 1994 - 
TL;DR: The hypothesis that the transforming capacity of HOX11 derives from its ability to alter the expression of genes regulating hematopoietic differentiation and that secondary mutations promoting cell survival or stimulating proliferation are required for progression to malignancy is supported.
Journal ArticleDOI

AXL/AKT axis mediated-resistance to BRAF inhibitor depends on PTEN status in melanoma.

Qiang Zuo, +9 more
- 19 Mar 2018 - 
TL;DR: This study has uncovered a mechanism by which PTEN status contributes to acquired resistance to BRAFi and offers a rational strategy to guide clinical testing in pre-identified subsets of patients who relapse during treatment with BRAFi.